Pharmaceutical Industry discussion, review, analysis, news and information.

Aromasin (from the family of drugs known as aromatase inhibitors) targets breast cancer by blocking the production of oestrogen and reducing serious side effects. This process may eventually become the gold-standard for cancer treatment.

Aromasin been identified as an effective weapon for treating the 80 per cent or so of breast cancers known as oestrogen-positive, but not for the aggressive HER2 form.

As reported by the scientists at the annual meeting of the American Society of Clinical Oncology recently, the drug cut the risk of death among postmenopausal women with hormone-sensitive primary breast cancer by 17 per cent compared with standard therapy.

Read more at Drug Researcher.